Xenetic Biosciences
XBIO
11 hedge funds and large institutions have $699K invested in Xenetic Biosciences in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
10% more funds holding
Funds holding: 10 → 11 (+1)
0% more ownership
Funds ownership: 0.04% → 0.04% (+0%)
38% less capital invested
Capital invested by funds: $1.13M → $699K (-$432K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$34.8K |
| 2 |
Bank of New York Mellon
New York
|
+$32.7K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.15K |
| 5 |
Barclays
London,
United Kingdom
|
+$4.54K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$37K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$303 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Royal Bank of Canada
Toronto,
Ontario, Canada
| $531K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $75K | +$26K | +86 | +29% |
|
|
3
Citadel Advisors
Miami,
Florida
| $22K | +$34.8K | +115 | New |
|
|
4
Bank of New York Mellon
New York
| $21K | +$32.7K | +108 | New |
|
|
PAM
5
Panagora Asset Management
Boston,
Massachusetts
| $20K | +$3.03K | +10 | +11% |
|
6
Acadian Asset Management
Boston,
Massachusetts
| $16K | – | – | – |
|
7
Morgan Stanley
New York
| $5K | +$303 | +1 | +4% |
|
|
8
Barclays
London,
United Kingdom
| $3K | +$4.54K | +15 | New |
|
|
9
UBS Group
Zurich,
Switzerland
| $3K | +$5.15K | +17 | New |
|
|
RE
10
RBC Europe
London,
United Kingdom
| $2.08K | – | – | – |
|
|
OIA
11
OneDigital Investment Advisors
Overland Park,
Kansas
| $1K | – | – | – |
|
|
VF
12
Virtu Financial
New York
| – | -$37K | -109 | Closed |
|
|
13
Bank of America
Charlotte,
North Carolina
| – | -$303 | -1 | Closed |
|
XBIO Hedge Fund Activity: Q4 2018 in Review
11 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q4 2018, worth a combined $699K — down 38% from $1.13M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new XBIO positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $34.8K. The largest seller was Virtu Financial, exiting entirely with an estimated $37K sold.
- 11 institutional investors held Xenetic Biosciences (XBIO) as of Q4 2018, up from 10 in Q3 2018.
- Funds reported $699K of Xenetic Biosciences stock for Q4 2018, down 38% quarter-over-quarter.
- 4 funds opened new Xenetic Biosciences positions in Q4 2018 and 3 closed out, a net change of +1 holder.
- The largest Xenetic Biosciences buyer in Q4 2018 was Citadel Advisors, an estimated $34.8K added.
- The largest Xenetic Biosciences seller in Q4 2018 was Virtu Financial, an estimated $37K sold.
Based on aggregated 13F filings for Q4 2018.